Fierce Healthcare October 21, 2021
Rebecca Torrence

The Food and Drug Administration has contracted with real-world evidence company Aetion to use their platform for the assessment of COVID-19 inpatient medical products, the company announced today.

The Aetion Evidence Platform, which analyzes real-world data (RWD) pulled from electronic health records and medical claims, will enable the FDA to assess inpatient COVID-19 treatments in real-time.

“As part of this agreement, they’ll be able to apply the best practice science to different real-world data sources that are fit for the purpose of understanding inpatient treatments, learn to do this themselves and be able to apply it now or to other questions that emerge in the future,” said Jeremy Rassen, Sc.D., co-founder of Aetion, in an interview with Fierce Healthcare.

Aetion’s...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), FDA, Govt Agencies, Healthcare System, Public Health / COVID, Technology
Related Articles:
FDA wants to boost trial innovation with new center at CDER
Stelara biosimilar from Alvotech, Teva approved by FDA
Scopio Labs Receives FDA Clearance For AI-Driven Bone Marrow Analysis Application
STAT+: Grocers are pushing legislation they claim would enhance food safety. Advocates say it would gut FDA rules
Look Before You Leap - Early Determination Of Product Classification And Regulatory Pathway For FDA-Regulated Products

Share This Article